CN101757174B - Medicinal composition with analgesic and anti-inflammatory effects - Google Patents
Medicinal composition with analgesic and anti-inflammatory effects Download PDFInfo
- Publication number
- CN101757174B CN101757174B CN2008102405276A CN200810240527A CN101757174B CN 101757174 B CN101757174 B CN 101757174B CN 2008102405276 A CN2008102405276 A CN 2008102405276A CN 200810240527 A CN200810240527 A CN 200810240527A CN 101757174 B CN101757174 B CN 101757174B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- weight
- radix
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition with analgesic and anti-inflammatory effects and a preparation method thereof. The medicinal composition of the invention comprises the raw materials of viscum album, teasel root, radix linderae, angelica, everflowering rose and the like; and the bulk drugs of semen litchi, bugleweed, Chinese pink herb and the like can added in the medicinal composition on the basis of the raw materials. The pharmacology and pharmacodynamic experiments show that: the medicinal composition of the invention has obvious effects of diminishing inflammation and improving the change of pathological histology on pelvic inflammation, an obvious anti-inflammatory effect on active and chronic inflammation, and a remarkable analgesic effect on acetic acid induced pain in a mouse without toxic or side effect.
Description
Invention field
The present invention relates to a kind of pharmaceutical composition, particularly a kind of pharmaceutical composition and preparation method thereof with analgesic and anti-inflammatory effects.
Background technology
Pelvic inflammatory disease is one of common gynecological disease, can involve endometrium, fallopian tube, ovary and peritoneum, comprises adnexitis, pelvioperitonitis, inflammation of pelvic connective tissue, pelvic abscess, pelvic thrombophlebitis etc.Pelvic inflammatory disease is suddenly delayed two kinds of branch acute pelvic inflammatory disease and chronic pelvic inflammatory diseases according to the state of an illness, and in recent years, the pelvic inflammatory disease sickness rate is on the rise.Chronic pelvic inflammatory disease is for seeing more clinically, and sickness rate is high and with the passing of time more not and can not show effect repeatedly, the serious harm women's is healthy.How effectively to treat pelvic inflammatory disease and become the great difficult problem in gynecological field.
At present, the western medical treatment pelvic inflammatory disease is mainly used antibiotic, and not only curative effect is undesirable, and can produce drug resistance, and has big toxic and side effects, brings very big misery to the patient.The Chinese traditional treatment pelvic inflammatory disease has the advantage of himself, and dialectical treatment is alleviated the state of an illness and can be obtained radical cure.At present, medicine is based on removing damp-heat class medicine, as FUKE QIANJIN PIAN, JINJI KELI, HUAHONG PIAN etc.Pelvic inflammatory disease by traditional Chinese medical science typing common damp heat downward flowing type, cold and damp stagnation type etc. are arranged, but said medicine is applicable to the damp heat downward flowing type pelvic inflammatory disease, for cold and damp stagnation type pelvic inflammatory disease, does not still have effective medicine at present.
Summary of the invention
The objective of the invention is to disclose a kind of pharmaceutical composition with analgesic and anti-inflammatory effects, another object of the present invention is the preparation method of open said composition.
The present invention seeks to be achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
Herba Taxilli 4-8 weight portion Radix Dipsaci 3-7 weight portion Radix Linderae 2-4 weight portion
Radix Angelicae Sinensis 2-4 weight portion Flos Rosae Chinensis 1-3 weight portion Radix Notoginseng 0.5-1.5 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The Herba Taxilli 6 weight portion Radix Dipsacis 5 weight portion Radixs Linderae 3 weight portions
Radix Angelicae Sinensis 3 weight portion Flos Rosae Chinensiss 2 weight portion Radix Notoginseng 1 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The Herba Taxilli 4.5 weight portion Radix Dipsacis 6.5 weight portion Radixs Linderae 3.5 weight portions
Radix Angelicae Sinensis 2.5 weight portion Flos Rosae Chinensiss 2.5 weight portion Radix Notoginseng 0.7 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The Herba Taxilli 7.5 weight portion Radix Dipsacis 3.5 weight portion Radixs Linderae 2.5 weight portions
Radix Angelicae Sinensis 3.5 weight portion Flos Rosae Chinensiss 1.5 weight portion Radix Notoginseng 1.3 weight portions.
Wherein, can also on above-mentioned raw materials medicine basis, add in the following crude drug one or more again:
Semen Litchi 2-4 weight portion Spica Prunellae 3-7 weight portion Herba Dianthi 2-4 weight portion.
Wherein, can also on above-mentioned raw materials medicine basis, add in the following crude drug one or more again:
Semen Litchi 3 weight portion Spica Prunellaes 5 weight portion Herba Dianthis 3 weight portions.
Wherein, can also on above-mentioned raw materials medicine basis, add in the following crude drug one or more again:
Semen Litchi 3.5 weight portion Spica Prunellaes 3.5 weight portion Herba Dianthis 2.5 weight portions.
Wherein, can also on above-mentioned raw materials medicine basis, add in the following crude drug one or more again:
Semen Litchi 2.5 weight portion Spica Prunellaes 6.5 weight portion Herba Dianthis 3.5 weight portions.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make granule, pill, capsule, tablet, soft capsule, slow releasing agent, oral liquid or injection according to common process.
Preparation of drug combination method of the present invention comprises the steps:
Get the above-mentioned raw materials medicine, the decocting that adds the 4-18 times of weight boils 1-3 time, each 1-3 hour, collecting decoction, filter, be concentrated to the concentrated solution that relative density is 1.00-1.20, drying, add conventional adjuvant, make granule, pill, capsule, tablet, soft capsule, slow releasing agent, oral liquid or injection according to conventional method.
Preparation of drug combination method of the present invention comprises the steps:
Get the above-mentioned raw materials medicine, the decocting that adds 12 times of weight boils 2 times, each 2 hours, collecting decoction, filter, be concentrated to the concentrated solution that relative density is 1.05-1.15, drying, add conventional adjuvant, make granule, pill, capsule, tablet, soft capsule, slow releasing agent, oral liquid or injection according to conventional method.
Pharmaceutical composition of the present invention is based on theory of Chinese medical science, has the effect of antalgic and inflammation relieving preferably, especially cold and damp stagnation type pelvic inflammatory disease there is tangible curative effect, pharmaceutical composition of the present invention is made up of crude drug such as Herba Taxilli, Radix Dipsaci, the Radix Linderae, Radix Angelicae Sinensis, Flos Rosae Chinensis, Radix Notoginseng, also can add crude drug such as Semen Litchi, Spica Prunellae, Herba Dianthi on this basis.Herba Taxilli, Radix Dipsaci invigorating the liver and kidney in the side, dampness removing is monarch drug; The Radix Linderae, Radix Angelicae Sinensis, Flos Rosae Chinensis blood circulation promoting and blood stasis dispelling, dispersing cold for relieving pain are ministerial drug; Radix Notoginseng, Semen Litchi, Spica Prunellae removing obstruction for relieving pain are adjuvant drug; The Herba Dianthi removing blood stasis stimulates the menstrual flow and is messenger drug.All medicine compatibilities, play altogether warming kidney and eliminating damp, the merit of blood stasis-eliminating and stagnation-dissipating.The pharmacological effect experiment shows: pharmaceutical composition of the present invention has tangible antiinflammatory for pelvic inflammatory disease and improves the effect that histopathology changes; For active chronic inflammation the obvious anti-inflammatory and anti effect is arranged, causing mice pain for acetic acid has remarkable analgesic activity, and has no side effect.
Following experimental example and embodiment further prove but are not limited to the present invention.
The experiment of experimental example 1 antiinflammatory action
1. the pharmaceutical composition of the embodiment of the invention 1 method preparation is to the content influence of PEG2 in rat carrageenan foot pawl swelling and the inflammatory tissue
60 of SD rats, male and female half and half, be divided into 6 groups at random: blank group, model control group, aspirin 0.25g/Kg group, the basic, normal, high dosage group of pharmaceutical composition of the present invention: 1g/Kg, 2g/Kg, 4g/Kg, each organizes equal gastric infusion 3d, every day, dosage gave at twice, and blank and model control group give the equal-volume normal saline.1h after the last administration, except that the blank group, the carrageenin 0.1ml of sufficient sole of the foot middle part, every rat left side subcutaneous injection 1% causes inflammation.After injection 0.5,1,2,3,5 hour, measure the following partial volume of ankle joint with drainage, calculate swelling percentage rate and suppression ratio respectively, rat paw volume before pedal swelling percentage rate (%)=(cause scorching back rat paw volume-cause scorching before rat paw volume) * 100%/cause is scorching the results are shown in Table 1.
Table 1 pharmaceutical composition of the present invention is to the influence of rat carrageenan pedal swelling (X ± S)
Annotate: compare with model control group
*P＜0.05,
*P＜0.01
Put to death rat after causing scorching 5 hours, 0.5cm cuts at the place inflammatory swelling foot on ankle joint, weighs, shreds, and it is immersed in the 5ml normal saline, centrifugal soak, draw supernatant 0.1ml, add the KOH solution 2ml of 0.5mol/l, at 50 ℃ of following isomerization 20min, be diluted to 20ml with methanol, measure absorbance down in 278nm, calculate the content of PEG2 in the inflammatory tissue, see Table 2.
Table 2 pharmaceutical composition of the present invention to the rat carrageenan pedal swelling after the influence (X ± S) of inflammatory tissue PEG2 content
Annotate: compare with model control group
*P＜0.05,
*P＜0.01
Experimental result shows: compare with the blank group, the remarkable swelling of rat paw (p＜0.01) after the modeling, compare with model control group, the caused rat paw edema of pharmaceutical composition 2g/kg of the present invention, 4g/kg group on Carrageenan has significant inhibitory effect (P＜0.01); Compare with blank, 5h after the modeling, PGE2 content significantly increases in the rat paw tissue, pharmaceutical composition 4g/kg of the present invention can suppress the generation (P＜0.05) of PEG2 in the rat model foot sole of the foot inflammatory tissue, point out pharmaceutical composition of the present invention that the rat acute inflammation is had obvious antagonism, its anti-inflammatory mechanisms may be by suppressing the generation of PEG2 in the inflammatory tissue.
2. the pharmaceutical composition of the embodiment of the invention 1 preparation is to the bullate influence of rat granuloma
50 of SD rats, male and female half and half, under the aseptic condition of 10% chloral hydrate (350mg/Kg) anesthesia, it is subcutaneous that the cotton balls (50mg) of will sterilizing is implanted each Mus axillary fossa.The postoperative rat is divided five groups at random: matched group, the prescriptions worth thousand gold 2g/Kg of gynecological group, the basic, normal, high dosage group of pharmaceutical composition of the present invention: 1g/Kg, 2g/Kg, 4g/Kg, 10 every group.Each treated animal gastric infusion, every day, dosage gave at twice, and continuous 7 days, model control group gave the equal-volume normal saline.1h after the last administration takes off vertebra with rat and puts to death, and peels off and take out the cotton balls granulation tissue, and weighing and deducting cotton balls heavily is the granulation tissue weight in wet base, cotton balls 110 ℃ of dry 24h in baking oven then, and weighing and deducting cotton balls heavily is the granulation tissue dry weight, the results are shown in Table 3:
Table 3 pharmaceutical composition of the present invention is to the bullate influence of rat granuloma (X ± S)
Annotate: compare with the blank group
*P＜0.05,
*P＜0.01
The result shows: compare with model, pharmaceutical composition continuous irrigation stomach of the present invention is after 7 days, 1g/Kg, and 2g/Kg, the 4g/Kg group has remarkable inhibitory action (p＜0.01) to granulation hyperplasia.Show that pharmaceutical composition of the present invention can suppress to simulate the experimental granulation hyperplasia of clinical inflammation later stage pathological change.
The pharmaceutical composition Pyrogentisinic Acid rubber cement of the present invention of experimental example 2: embodiment 1 preparation causes the influence of rat pelvic inflammatory disease model
60 of SD female rats, wherein water 24h is can't help in 50 fasting, 10% chloral hydrate (350mg/Kg) intraperitoneal anesthesia, cut off the lower abdomen mesal median seta, routine disinfection in hypogastric region median incision 3cm, exposes the uterus, with 4 number sword-shaped needle heads on crotch right side, uterus towards ovary direction inserting needle, slowly inject 25% phenol rubber cement 0.1ml.Does not inject as own control in the opposite side uterus, and after operation finished, abdomen was closed in layering, the sterile surgical district, and antiseptic gauze covers.10 rats only open abdomen and close the abdomen operation in addition, do not inject the phenol rubber cement, as Sham-operated control group.
7d begins administration after the modeling, the modeling rat is divided 5 groups at random: model control group, the prescriptions worth thousand gold 2g/Kg of gynecological group, the basic, normal, high dosage group of pharmaceutical composition of the present invention: 1g/Kg, 2g/Kg, 4g/Kg, every group 10, successive administration treatment 15 days, every day, dosage gave at twice, and sham-operation contrast and model control group give the equal-volume normal saline.1h after the last administration, each organizes rat, under 10% chloral hydrate (350mg/Kg) narcotism, abdominal aortic blood, anticoagulant heparin, the preparation anticoagulated blood, LG-R80B type blood viscosity instrument detects hemorheology index.Peel off uterus, both sides and ovary simultaneously, weigh, calculate the dirty body ratio of uterus ovary; Uterus ovary conventional H E dyeing subsequently, the histopathology intensity of variation in observation uterus, lesion degree carries out range, and grade scale is as follows:
"-": endometrium does not have obvious cell infiltration, and slight epithelial hyperplasia can be arranged, and does not have obvious epithelial cell apoptosis.
"+": the slight cell infiltration of endometrium, slight epithelial hyperplasia, minority epithelial cell apoptosis.
" ++ ": the slight cell infiltration of endometrium, moderate epithelial hyperplasia, moderate epithelial cell apoptosis.
" +++": endometrium moderate cell infiltration, moderate epithelial hyperplasia, moderate epithelial cell apoptosis.
" ++ ++ ": endometrium severe cell infiltration, severe epithelial hyperplasia, severe epithelial cell apoptosis.
Experimental result sees Table 4 and table 5:
Table 4 pharmaceutical composition of the present invention is to the influence of rat pelvic inflammatory disease model
Annotate: compare with model control group
*P＜0.05,
*P＜0.01
Table 5 pharmaceutical composition of the present invention is to the hemorheological influence of pelvic inflammatory disease rat model (n=10, X ± S)
Annotate: compare with model control group
*P＜0.05,
*P＜0.01
The result shows, compares with sham operated rats, and the dirty body of model group rat uterus is than significantly increasing (p＜0.01), and tissue pathologies change is remarkable; Pharmaceutical composition 2g/kg of the present invention, the 4g/kg group can significantly reduce the dirty body in rat model uterus than (p＜0.05), and the rat endometrium pathological changes is had certain therapeutical effect.
With sham operated rats relatively, the hemorheology index of model group all has remarkable rising, occurs obviously densely, glues symptom (p＜0.01).Pharmaceutical composition 2g/Kg of the present invention, 4g/Kg successive administration 15 days, to the rat model height, in, the effect (p＜0.05) that all is significantly improved of whole blood viscosity under the low shear rate, plasma viscosity, and obviously reduce hematocrit value (p＜0.05, p＜0.01), prompting pharmaceutical composition of the present invention has the effect of certain blood circulation promoting and blood stasis dispelling.
The pharmaceutical composition analgesic activity experiment of the present invention of experimental example 3 embodiment 1 method preparation
Get 50 of Kunming mouses, male and female half and half, be divided into 5 groups at random: model control group, the prescriptions worth thousand gold 2g/Kg of gynecological group, the basic, normal, high dosage group of pharmaceutical composition of the present invention: 1.5g/Kg, 3g/Kg, 6g/Kg, 10 every group, successive administration treatment 7 days, every day, dosage gave at twice, and model control group gives the equal-volume normal saline.Injection 0.7% acetic acid 0.1ml/10g body weight in the 1h after the last administration, mouse peritoneal.Observe and to turn round the body number of times in the 15min, calculate and turn round the body suppression ratio.
Respectively organize equal tail vein iv behind the 30min and give 0.5% azovan blue normal saline solution 0.1mL/10g, take off vertebra behind the 20min and put to death mice, open the abdominal cavity, with normal saline thorough washing abdominal cavity, merge cleaning mixture, be settled to 10ml, the centrifugal 15min of cleaning mixture 3000r/min, get supernatant and survey trap in the 590nm place, calculate and ooze out suppression ratio, the results are shown in Table 6:
Turn round body suppression ratio (%)=(model group is turned round body number-administration group and turned round the body number) * 100%/model group and turn round the body number
Ooze out suppression ratio (%)=(model group trap-administration group trap) * 100%/model group trap
Table 6 pharmaceutical composition Dichlorodiphenyl Acetate of the present invention causes the influence (X ± S) of mouse writhing reaction and abdominal cavity capillary permeability thereof
Annotate: compare with model control group
*P＜0.05,
*P＜0.01
Experimental result shows: compare with model control group, pharmaceutical composition 3g/Kg of the present invention, 6g/Kg group can significantly reduce mouse writhing number of times (p＜0.01), simultaneously, compare with model control group, pharmaceutical composition 3g/Kg of the present invention, 6g/Kg group can obviously reduce mouse peritoneal capillary permeability (p＜0.01).Illustrate that pharmaceutical composition of the present invention has analgesia and antiinflammatory action.
Following embodiment all can realize the effect of above-mentioned experimental example.
The specific embodiment
Embodiment 1: granule
Herba Taxilli 6kg Radix Dipsaci 5kg Radix Linderae 3kg
Radix Angelicae Sinensis 3kg Flos Rosae Chinensis 2kg Radix Notoginseng 1kg
Semen Litchi 3kg Spica Prunellae 5kg Herba Dianthi 3kg;
Get the above-mentioned raw materials medicine, the decocting that adds 12 times of weight boils 2 times, and each 2 hours, collecting decoction filtered, be concentrated to the concentrated solution that relative density is 1.05-1.15, drying adds adjuvant, and mixing is granulated, drying promptly gets granule 10000g, takes every day 2 times, each 10g.
Embodiment 2: capsule
Herba Taxilli 4.5kg Radix Dipsaci 6.5kg Radix Linderae 3.5kg
Radix Angelicae Sinensis 2.5kg Flos Rosae Chinensis 2.5kg Radix Notoginseng 0.7kg
Semen Litchi 3kg;
Get the above-mentioned raw materials medicine, the decocting that adds 6 times of weight boiled 3 hours, got decocting liquid, filtered, and was concentrated to the concentrated solution that relative density is 1.05-1.10, and drying adds conventional adjuvant, makes capsule according to a conventional method.
Embodiment 3: tablet
Herba Taxilli 7.5kg Radix Dipsaci 3.5kg Radix Linderae 2.5kg
Radix Angelicae Sinensis 3.5kg Flos Rosae Chinensis 1.5kg Radix Notoginseng 1.3kg
Semen Litchi 3.5kg Spica Prunellae 3.5kg;
Get the above-mentioned raw materials medicine, the decocting that adds 15 times of weight boils 3 times, and each 1 hour, collecting decoction filtered, and is concentrated to the concentrated solution that relative density is 1.10-1.15, and drying adds conventional adjuvant, makes tablet according to a conventional method.
Embodiment 4: pill
Herba Taxilli 6kg Radix Dipsaci 5kg Radix Linderae 3kg
Radix Angelicae Sinensis 3kg Flos Rosae Chinensis 2kg Radix Notoginseng 1kg
Spica Prunellae 6.5kg Herba Dianthi 3.5kg;
Get the above-mentioned raw materials medicine, add conventional adjuvant, make pill according to a conventional method.
Embodiment 5: soft capsule
Herba Taxilli 4.5kg Radix Dipsaci 6.5kg Radix Linderae 3.5kg
Radix Angelicae Sinensis 2.5kg Flos Rosae Chinensis 2.5kg Radix Notoginseng 0.7kg;
Get the above-mentioned raw materials medicine, add conventional adjuvant, make soft capsule according to a conventional method.
Embodiment 6: oral liquid
Herba Taxilli 7.5kg Radix Dipsaci 3.5kg Radix Linderae 2.5kg
Radix Angelicae Sinensis 3.5kg Flos Rosae Chinensis 1.5kg Radix Notoginseng 1.3kg
Semen Litchi 3kg Spica Prunellae 5kg Herba Dianthi 3kg;
Get the above-mentioned raw materials medicine, add conventional adjuvant, make oral liquid according to a conventional method.
Embodiment 7: injection
Herba Taxilli 6kg Radix Dipsaci 5kg Radix Linderae 3kg
Radix Angelicae Sinensis 3kg Flos Rosae Chinensis 2kg Radix Notoginseng 1kg
Spica Prunellae 5kg;
Get the above-mentioned raw materials medicine, add conventional adjuvant, make injection according to a conventional method.
Claims (13)
1. pharmaceutical composition with analgesic and anti-inflammatory effects is characterized in that the crude drug of this pharmaceutical composition consists of:
Herba Taxilli 4-8 weight portion Radix Dipsaci 3-7 weight portion Radix Linderae 2-4 weight portion
Radix Angelicae Sinensis 2-4 weight portion Flos Rosae Chinensis 1-3 weight portion Radix Notoginseng 0.5-1.5 weight portion
Semen Litchi 2-4 weight portion Spica Prunellae 3-7 weight portion Herba Dianthi 2-4 weight portion.
2. pharmaceutical composition as claimed in claim 1 is characterized in that the proportion relation of following Six-element crude drug in this pharmaceutical composition is:
The Herba Taxilli 6 weight portion Radix Dipsacis 5 weight portion Radixs Linderae 3 weight portions
Radix Angelicae Sinensis 3 weight portion Flos Rosae Chinensiss 2 weight portion Radix Notoginseng 1 weight portion.
3. pharmaceutical composition as claimed in claim 1 is characterized in that the proportion relation of following Six-element crude drug in this pharmaceutical composition is:
The Herba Taxilli 4.5 weight portion Radix Dipsacis 6.5 weight portion Radixs Linderae 3.5 weight portions
Radix Angelicae Sinensis 2.5 weight portion Flos Rosae Chinensiss 2.5 weight portion Radix Notoginseng 0.7 weight portion.
4. pharmaceutical composition as claimed in claim 1 is characterized in that the proportion relation of following Six-element crude drug in this pharmaceutical composition is:
The Herba Taxilli 7.5 weight portion Radix Dipsacis 3.5 weight portion Radixs Linderae 2.5 weight portions
Radix Angelicae Sinensis 3.5 weight portion Flos Rosae Chinensiss 1.5 weight portion Radix Notoginseng 1.3 weight portions.
5. as the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that the proportion relation of following three flavor crude drug in this pharmaceutical composition is:
Semen Litchi 3 weight portion Spica Prunellaes 5 weight portion Herba Dianthis 3 weight portions.
6. as the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that the proportion relation of following three flavor crude drug in this pharmaceutical composition is:
Semen Litchi 3.5 weight portion Spica Prunellaes 3.5 weight portion Herba Dianthis 2.5 weight portions.
7. as the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that the proportion relation of following three flavor crude drug in this pharmaceutical composition is:
Semen Litchi 2.5 weight portion Spica Prunellaes 6.5 weight portion Herba Dianthis 3.5 weight portions.
8. as the arbitrary described preparation of drug combination method of claim 1-7, it is characterized in that this method comprises the steps:
Get the above-mentioned raw materials medicine, the decocting that adds the 4-18 times of weight boils 1-3 time, each 1-3 hour, collecting decoction, filter, be concentrated to the concentrated solution that relative density is 1.00-1.20, drying, add conventional adjuvant, make granule, pill, capsule, tablet, slow releasing agent, oral liquid or injection according to conventional method.
9. preparation of drug combination method as claimed in claim 8 is characterized in that this method comprises the steps:
Get the above-mentioned raw materials medicine, the decocting that adds 12 times of weight boils 2 times, each 2 hours, collecting decoction, filter, be concentrated to the concentrated solution that relative density is 1.05-1.15, drying, add conventional adjuvant, make granule, pill, capsule, tablet, slow releasing agent, oral liquid or injection according to conventional method.
10. as the arbitrary described preparation of drug combination method of claim 1-7, it is characterized in that this method comprises the steps:
Get the above-mentioned raw materials medicine, the decocting that adds the 4-18 times of weight boils 1-3 time, and each 1-3 hour, collecting decoction filtered, and is concentrated to the concentrated solution that relative density is 1.00-1.20, and drying adds conventional adjuvant, makes soft capsule according to conventional method.
11. preparation of drug combination method as claimed in claim 10 is characterized in that this method comprises the steps:
Get the above-mentioned raw materials medicine, the decocting that adds 12 times of weight boils 2 times, and each 2 hours, collecting decoction filtered, and is concentrated to the concentrated solution that relative density is 1.05-1.15, and drying adds conventional adjuvant, makes soft capsule according to conventional method.
12. have application in the medicine of analgesic and anti-inflammatory effects in preparation as the arbitrary described pharmaceutical composition of claim 1-7.
13. application as claimed in claim 12 is characterized in that wherein said antalgic and inflammation relieving mainly is meant the treatment pelvic inflammatory disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102405276A CN101757174B (en) | 2008-12-23 | 2008-12-23 | Medicinal composition with analgesic and anti-inflammatory effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102405276A CN101757174B (en) | 2008-12-23 | 2008-12-23 | Medicinal composition with analgesic and anti-inflammatory effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101757174A CN101757174A (en) | 2010-06-30 |
| CN101757174B true CN101757174B (en) | 2011-11-02 |
Family
ID=42488656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102405276A Expired - Fee Related CN101757174B (en) | 2008-12-23 | 2008-12-23 | Medicinal composition with analgesic and anti-inflammatory effects |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101757174B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079156A (en) * | 1993-02-03 | 1993-12-08 | 樊自立 | Medicine " Kangyantongjingting " for anti-inflammatory treatment and curing dysmenorrhea |
-
2008
- 2008-12-23 CN CN2008102405276A patent/CN101757174B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079156A (en) * | 1993-02-03 | 1993-12-08 | 樊自立 | Medicine " Kangyantongjingting " for anti-inflammatory treatment and curing dysmenorrhea |
Non-Patent Citations (1)
| Title |
|---|
| 黄英.中医药治疗慢性盆腔炎研究概况.《右江名族医学院学报》.2008,(第3期),490-492. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101757174A (en) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104758691A (en) | Traditional Chinese medicine for treating overactive bladder after prostate electrocision | |
| CN104274788A (en) | Traditional Chinese medicine composition for treating morbid leucorrhea due to liver-fire and damp-heat in women and preparation method of traditional Chinese medicine composition | |
| CN101342356B (en) | Traditional Chinese medicine preparation for congestion retardarce, haemal tube obstruction and preparation method thereof | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN102698014A (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
| CN100558394C (en) | A kind of Chinese medicine composition is used to prepare the medicine for the treatment of endometriosis | |
| CN104906465A (en) | Traditional Chinese medicine blood-stasis dispersing composition for treating woman chronic pelvic inflammation and preparation method thereof | |
| CN101732602A (en) | Medicament for treating calculi and preparation method thereof | |
| CN101607067B (en) | Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof | |
| CN103599263B (en) | A kind of Chinese medicine for hemorrhoid and preparation method thereof | |
| CN102670977A (en) | Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition | |
| CN103316166B (en) | Tibetan medicine for treating hemorrhoids and preparation method thereof | |
| CN102579528B (en) | Medicine composition for preventing and curing prostatic diseases | |
| CN101757174B (en) | Medicinal composition with analgesic and anti-inflammatory effects | |
| CN103893701B (en) | A kind of Chinese medicine composition alleviating patients suffering from postoperative pain and promote wound healing | |
| CN103751298B (en) | A kind of Chinese medicinal enema for the treatment of chronic non-specific ulcerative colitis | |
| CN103623122B (en) | A kind of Chinese medicine for hemorrhoid and preparation method thereof | |
| CN102274433A (en) | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN102755435B (en) | Chinese medicinal preparation for treating cutaneous pruritus and preparation method thereof | |
| CN104958416A (en) | Chinese medicinal preparation for treating sciatica and preparation method thereof | |
| CN1733197B (en) | Medicine for curing chronic prostatitis and process for preparing the same | |
| CN104248674A (en) | Traditional Chinese medicine for treating burns and scalds | |
| CN1318066C (en) | Medicine for treating dysmenorrhes and preparation thereof | |
| CN103768290A (en) | Traditional Chinese medicine composition for treating synovitis and preparation method thereof | |
| CN102614375B (en) | Traditional Chinese medicine compound for tonifying kidney, strengthening yang and treating impotence and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111102 Termination date: 20191223 |